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Reducing the use of inappropriate abbreviations in prescriptions
NR Samaranayake1, STD Cheung2, CMW Chui2, BMY Cheung1
1Department of Medicine, The University of Hong Kong, Hong Kong
2Department of Pharmacy, Queen Mary Hospital, Hong Kong
introduction: Inappropriate use of abbreviations in prescriptions affects patient safety. 
Objectives: We investigated the effect of the ‘Do Not Use’ list on the use of such inappropriate abbreviations 
and the adherence to the Hospital Authority’s approved ‘Standard Abbreviations in Prescribing’ list.
Methods: We analysed the use of prescribing abbreviations in prescriptions before and after the introduction of 
the ‘Do Not Use’ list and the rate of related medication incidents in Queen Mary Hospital over this period.
Results: A total of 12 639 drug items were analysed. The use of abbreviations discouraged by the ‘Do Not Use’ 
list was 9% per number of drugs prescribed before its introduction in October 2008, which was reduced to 1% 
after the intervention. Commonly used abbreviations related to the ‘Do Not Use’ list were ‘QD’, ‘mcg’ and ‘units’, 
which were used at a rate of 5.5%, 1% and 2% at baseline and reduced to 0.5%, 0.3% and 0.4% respectively after 
its introduction. 8% of the drugs were abbreviated drug names of which 49% were not found in the ‘Standard 
Abbreviations’ list. Non-approved abbreviations were also used to indicate the ‘route of administration’ at a 
rate of 10%. During 2008–2010, one medication incident directly related to the ‘Do Not Use’ list and 16 incidents 
related to the use of other non-approved abbreviations (four incidents having a severity score of two or more 
and 13 incidents scoring one) were reported. 
Conclusions: The introduction of the ‘Do Not Use’ list was very effective in reducing the use of inappropriate 
abbreviations. However, the use of non-approved abbreviations is common. Enlarging the ‘Do Not Use’ list is 
recommended.
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Evidence of serologic activity in chronic hepatitis B after hepatitis B surface antigen 
seroclearance
WK Seto, DKH Wong, CL Lai, JCH Yuen, T Tong, J Fung, IFN Hung, MF Yuen
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong
Background: Possible serologic activity after hepatitis B surface antigen (HBsAg) seroclearance in chronic 
hepatitis B (CHB) has not been thoroughly investigated. 
Methods: We determined the levels of serum HBV DNA, hepatitis B core-related antigen (HBcrAg) and 
linearized HBsAg (CLEIA prototype) in CHB patients after HBsAg seroclearance. A total of 329 CHB patients 
(72.0% male) with documented HBsAg seroclearance were recruited. 
Results: The median time interval from presentation to HBsAg seroclearance was 69.4 months. The median 
age of HBsAg seroclearance was 50 years. Serum HBV DNA, HBcrAg and linearized HBsAg were performed 
at a median time interval of 11.2 months after HBsAg loss. 85 (25.8%) and 69 (21%) of patients had detectable 
linearized HBsAg and HBcrAg, respectively. 133 patients (40.4%) had either one or both serologic markers 
detectable whereas serum HBV DNA was detectable in only seven (2.1%) patients. There was no correlation 
between linearized HBsAg and HBcrAg levels (r=0.095, P=0.924). There was no difference in the incidences of 
detectable linearized HBsAg and HBcrAg between patient samples taken at 6-12 and >12 months after HBsAg 
seroclearance (P=0.146 and 0.079 respectively). Among patients with detectable serology, an increased time 
interval after HBsAg seroclearance was not associated with any significant change in median levels of linearized 
HBsAg (P=0.581) and HBcrAg (P=0.951). 
Conclusion: Using these novel linearized HBsAg and HBcrAg assays, viral serologic activities were demonstrated 
in more than 40% of CHB patients after HBsAg seroclearance. These tests may have potential applications in 
diagnosing and prognosticating CHB patients with HBsAg seroclearance.
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